Skip to Content

Etravirine Pregnancy and Breastfeeding Warnings

Etravirine is also known as: Intelence

Etravirine Pregnancy Warnings

An Antiretroviral Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnant women exposed to etravirine. Healthcare providers are encouraged to register patients by calling 1-800-258-4263 (USA).

Etravirine has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. Etravirine is only recommended for use during pregnancy when benefit outweighs risk.

See references

Etravirine Breastfeeding Warnings

There are no data on the excretion of etravirine into human milk. The manufacturer recommends that due to the potential for HIV transmission and the potential for adverse reactions in nursing infants, mothers should not breast-feed while taking etravirine. The U.S. Public Health Service Centers for Disease Control and Prevention advise HIV-infected women not to breast-feed to avoid postnatal transmission of HIV to a child who may not yet be infected.

See references

References for pregnancy information

  1. Johnson LB, Saravolatz LD "Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor." Clin Infect Dis (2009):
  2. "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.

References for breastfeeding information

  1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. National Institute of Health "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL:" ([2011 Sep 14]):
  2. Johnson LB, Saravolatz LD "Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor." Clin Infect Dis (2009):
  3. "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.
  4. "Infant feeding and transmission of human immunodeficiency virus in the United States." Pediatrics 131 (2013): 391-6

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.